Evidence map›Paper›PMID 31770141›Full record

ArticleClinical and translational gastroenterology2019

Response to Liu et al.

Mark O Goodarzi, David C Whitcomb

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Mark O GoodarziDivision of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
David C WhitcombDivision of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Pittsburgh and UPMC Medical Center, Pittsburgh, Pennsylvania, USA.

Funding

Transgenic & Knock-out MouseP30DK063491 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI PETER J TONTONOZ · 2003 to 2026
$40.4M
UPMC Clinical Center for the Study of Chronic Pancreatitis and DiabetesU01DK108306 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Frederico G. S. Toledo, Dhiraj Yadav · 2015 to 2026
$6.4M
Pathophysiology, Epidemiology, and Prevention of Pancreatogenic Diabetes - Administrative SupplementU01DK108314 · NIDDK · CEDARS-SINAI MEDICAL CENTER · PI Mark Goodarzi, Stephen J. Pandol · 2015 to 2026
$6.1M
North American Pancreatitis Study 2 (NAPS2)R01DK061451 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WHITCOMB, DAVID CLEMENT · 2002 to 2010
$4.9M
NIDDK NIH HHS P30 DK063491NIDDK NIH HHS R01 DK061451NIDDK NIH HHS U01 DK108306NIDDK NIH HHS U01 DK108314
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Diabetes Mellitus, Type 2Pancreatitis, ChronicHumansRisk Factors

Identifiers

PMID31770141
PMCPMC6890276

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.